.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,858,228

« Back to Dashboard

Details for Patent: 6,858,228

Title: Solid oral dosage forms of valsartan
Abstract:The present invention is concerned with solid oral dosage forms of comprising a) an active agent selected from valsartan and optionally HCTZ, and b) Pharmaceutically acceptable additives suitable for the preparation of solid oral dosage forms by compression methods.
Inventor(s): Katakuse; Yoshimitsu (Hirakata, JP), Kohlmeyer; Manfred (Basel, CH), Taike; Takashi (Kobe, JP), Wagner; Robert Frank (Neshanic Station, NJ), Yamato; Fujiki (Takarazuka, JP)
Assignee: Novartis AG (Basel, CH)
Filing Date:Sep 20, 2002
Application Number:10/251,009
Claims:1. A compressed solid oral dosage form comprising: a) an active agent containing an effective amount of valsartan or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable additive

wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid oral dosage form, said solid oral dosage form comprising:

2. A compressed solid oral dosage form according to claim 1 wherein said dosage from exhibits accelerated release of the active agent.

3. A compressed solid oral dosage form comprising: a) an active agent containing an effective amount of valsartan or a pharmaceutically acceptable salt thereof and b) at least one pharmaceutically acceptable additive

wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid oral dosage form, said solid oral dosage form comprising:

4. The compressed solid oral dosage form according to claim 3 wherein said dosage form exhibits accelerated release of the active agent.

5. A compressed solid oral dosage form comprising: a) an active agent containing an effective amount of valsartan or a pharmaceutically acceptable salt thereof and b) at least one pharmaceutically acceptable additive

wherein the active agent is present in an amount of more than 35% by weight based on the total weight of the compressed solid oral dosage form, said solid oral dosage form comprising:

6. The compressed solid oral dosage form according to claim 5 wherein said dosage form exhibits accelerated release of the active agent.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc